The NHLI carries out cutting edge quality research in order to advance healthcare in the fields of cardiovascular and respiratory science. Through this, we aim to develop better treatment and understanding of common conditions of the heart and lung. In the latest assessment of research quality at UK institutions (REF 2014) Imperial College was rated third in the UK in Clinical Medicine, where the majority of the NHLI's research falls. The NHLI has a proud history as a well respected research institute that we maintain today through cutting edge research and collaborations with top hospitals and other affiliates.
The NHLI is at the forefront of the diagnosis, prevention and treatment of heart disease, and is the focus of Imperial College's research in cardiovascular science. Cardiovascular research at the NHLI is recognised for its excellence both nationally and internationally, with established research strengths and hospital links which build on its current and emerging scientific strengths and that strongly relate to major unmet clinical needs. There are excellent opportunities for translation to clinical needs, with the application of laboratory-based and population-based discovery research into therapeutic and preventive targets, tested in cell culture and animal models of human disease then in proof-of-principle studies in man, before being studied in larger populations.
Our Respiratory Medicine group has the largest critical mass of respiratory researchers within the UK and enjoys a pre-eminent position nationally and internationally as a place of outstanding research into respiratory disease. This position is based on many factors, including its reputation for world-leading research and its excellent clinical base and service for patients with severe lung disease. Imperial College contains world-class groups investigating respiratory infections, cell and leukocyte biology, airways and allergic diseases, integrative physiology and pharmacology, public health and genetics and genomics.